Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy
NCT ID: NCT05073094
Last Updated: 2021-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
80 participants
INTERVENTIONAL
2021-10-06
2023-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery
NCT00415701
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
NCT03532802
Esmolol in Cardiac Surgery
NCT00959569
Metoprolol to Reduce Perioperative Myocardial Injury
NCT03138603
Beta-blocker Before Extubation
NCT00563238
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Esmolol
1 mg/kg (max. 100 mg) as a bolus before aortic cross-clamping and 2 mg/kg (max. 200 mg) in the cardioplegia solution
Esmolol
Esmolol injected intravenously and added to cardioplegia solution
Placebo
Equivalent volume of saline as a bolus before aortic cross-clamping and in the cardioplegic solution
Placebo
Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esmolol
Esmolol injected intravenously and added to cardioplegia solution
Placebo
Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
* Patient with hypertrophic obstructive cardiomyopathy undergoing surgery under cardiopulmonary bypass
Exclusion Criteria
* Urgent/emergent surgery
* Administration of esmolol in 30 days before randomization
* Participation in other randomized trial during same hospitalization
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meshalkin Research Institute of Pathology of Circulation
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
E. Meshalkin National Medical Research Center
Novosibirsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Related Info
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BETABLOCK-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.